Capsule Summary Slidesets

Share

Program Content

Activities

  • Venetoclax + Navitoclax in ALL/LL
    Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2019

    Expires: December 07, 2020

  • Frontline Ponatinib in ALL
    First-line Hyper-CVAD Plus Ponatinib in Adults With Ph+ Acute Lymphoblastic Leukemia: Long-term Safety and Efficacy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2019

    Expires: December 08, 2020

  • R/R AML After VEN + HMA
    Outcomes in R/R AML After First-line Treatment With Venetoclax Plus a Hypomethylating Agent
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

    Expires: December 11, 2020

  • TDT and Prognosis in AML
    Analysis: Prognostic Effect of Time From Diagnosis to Treatment in Newly Diagnosed AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

    Expires: December 11, 2020

  • QUAZAR AML-001
    QUAZAR AML-001: Phase III Study of CC-486 Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Remission
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2019

    Expires: December 13, 2020

  • FLAG-IDA plus Venetoclax in AML
    Phase Ib/II Study: FLAG-IDA Plus Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • ENA + AZA in ND mIDH2 AML
    Interim Phase II Results From AG221-AML-005: Enasidenib + Azacitidine vs Azacitidine Alone in Newly Diagnosed AML With IDH2 Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2019

    Expires: December 15, 2020

  • Ph+ ALL: Dasatinib + Blinatumomab
    Updated Analysis of Frontline Dasatinib + Blinatumomab in Patients With Newly Diagnosed Ph+ ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2019

    Expires: December 16, 2020

  • Blinatumomab in B-ALL
    Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

  • E2906: DAC Maintenance
    ECOG-ACRIN E2906: Maintenance Decitabine After Response to Intensive Therapy in Older AML Patients
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2019

    Expires: December 18, 2020

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company